Glofitamab
- Generic Name
- Glofitamab
- Brand Names
- Columvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2229047-91-8
- Unique Ingredient Identifier
- 06P3KLK2J8
- Background
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...
- Indication
Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Associated Therapies
- -
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06670105
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06656234
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT06656221
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06624085
- Locations
- 🇺🇸
Saddleback Memorial Medical Center, Laguna Hills, California, United States
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Target Recruit Count
- 22
- Registration Number
- NCT06570447
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, China
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06567366
- Locations
- 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 100
- Registration Number
- NCT06558604
- Locations
- 🇧🇪
Az Sint-Jan Brugge - Oostende Av, Brugge, Belgium
🇧🇪Institut Jules Bordet, Brussel, Belgium
🇧🇪Chu de Liege, Liège, Belgium
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06552572
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 178
- Registration Number
- NCT06534437
- Locations
- 🇵🇱
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska, Poland
🇵🇱Szpitale Pomorskie Sp. z o.o., Gdynia, Poland
🇵🇱Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy, Gliwice, Poland
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Target Recruit Count
- 50
- Registration Number
- NCT06497452
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.